Terms: = Lymphoma AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Treatment
119 results:
1. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract] [Full Text] [Related]
2. A GPX4 non-enzymatic domain and mdm2 targeting peptide PROTAC for acute lymphoid leukemia therapy through ferroptosis induction.
Niu F; Yang R; Feng H; Liu Y; Liu R; Ma B
Biochem Biophys Res Commun; 2023 Dec; 684():149125. PubMed ID: 37897912
[TBL] [Abstract] [Full Text] [Related]
3. Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia.
Johansson KB; Zimmerman MS; Dmytrenko IV; Gao F; Link DC
Leukemia; 2023 Dec; 37(12):2356-2366. PubMed ID: 37838759
[TBL] [Abstract] [Full Text] [Related]
4. Susceptibility of pediatric acute lymphoblastic leukemia to STAT3 inhibition depends on p53 induction.
Gasparoli L; Virely C; Tsakaneli A; Che N; Edwards D; Bartram J; Hubank M; Pal D; Heidenreich O; Martens JHA; De Boer J; Williams O
Haematologica; 2024 Apr; 109(4):1069-1081. PubMed ID: 37794795
[TBL] [Abstract] [Full Text] [Related]
5. Integrative analyses reveal outcome-associated and targetable molecular partnerships between TP53, BRD4, TNFRSF10B, and CDKN1A in diffuse large B-cell lymphoma.
Forberg AL; Unrau J; Weber KS; Rutz AC; Lund S; Guidinger J; Pelzel A; Hauge J; Hemmen AJ; Hartert KT
Ann Hematol; 2024 Jan; 103(1):199-209. PubMed ID: 37792064
[TBL] [Abstract] [Full Text] [Related]
6. Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia.
Ishikawa C; Mori N
Med Oncol; 2023 May; 40(6):172. PubMed ID: 37165174
[TBL] [Abstract] [Full Text] [Related]
7. Synthesis and biological evaluation of dual mdm2/XIAP inhibitors based on the tetrahydroquinoline scaffold.
Albadari N; Xie Y; Liu T; Wang R; Gu L; Zhou M; Wu Z; Li W
Eur J Med Chem; 2023 Jul; 255():115423. PubMed ID: 37130471
[TBL] [Abstract] [Full Text] [Related]
8. Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
Tucker ER; Jiménez I; Chen L; Bellini A; Gorrini C; Calton E; Gao Q; Che H; Poon E; Jamin Y; Martins Da Costa B; Barker K; Shrestha S; Hutchinson JC; Dhariwal S; Goodman A; Del Nery E; Gestraud P; Bhalshankar J; Iddir Y; Saberi-Ansari E; Saint-Charles A; Geoerger B; Marques Da Costa ME; Pierre-Eugène C; Janoueix-Lerosey I; Decaudin D; Nemati F; Carcaboso AM; Surdez D; Delattre O; George SL; Chesler L; Tweddle DA; Schleiermacher G
Clin Cancer Res; 2023 Apr; 29(7):1317-1331. PubMed ID: 36602782
[TBL] [Abstract] [Full Text] [Related]
9. Stilbene B10 induces apoptosis and tumor suppression in lymphoid Raji cells by BTK-mediated regulation of the KRAS/HDAC1/EP300/PEBP1 axis.
Varier KM; Dan G; Liu W; Wu G; Xiao C; Lei H; Ling T; Jiang Y; Chen Y; Ben-David Y; Li Y; Zhang N; Gajendran B; Shen X
Biomed Pharmacother; 2022 Dec; 156():113887. PubMed ID: 36274467
[TBL] [Abstract] [Full Text] [Related]
10. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
Zhai Y; Tang Q; Fang DD; Deng J; Zhang K; Wang Q; Yin Y; Fu C; Xue SL; Li N; Zhou F; Yang D
Clin Cancer Res; 2023 Jan; 29(1):183-196. PubMed ID: 36240005
[TBL] [Abstract] [Full Text] [Related]
11. IDO1 plays a tumor-promoting role via mdm2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma.
Sun C; Li M; Zhang L; Sun F; Chen H; Xu Y; Lan Y; Zhang L; Lu S; Zhu J; Huang J; Wang J; Hu Y; Feng Y; Zhang Y
Cell Death Dis; 2022 Jun; 13(6):572. PubMed ID: 35760783
[TBL] [Abstract] [Full Text] [Related]
12. Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia.
Ishikawa C; Mori N
Invest New Drugs; 2022 Aug; 40(4):718-727. PubMed ID: 35477814
[TBL] [Abstract] [Full Text] [Related]
13. Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions.
Umehara K; Cleary Y; Fowler S; Parrott N; Tuerck D
Drug Metab Dispos; 2022 Mar; 50(3):214-223. PubMed ID: 34937801
[TBL] [Abstract] [Full Text] [Related]
14. [Effect of RITA on TP53 Mutant Human Mantle Cell lymphoma Cell Line and Its Mechanism].
Hua JY; Zhou XH; Wang Y; Xu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1780-1784. PubMed ID: 34893110
[TBL] [Abstract] [Full Text] [Related]
15. Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to mdm2 inhibitors in vivo.
Zhang X; Zhang R; Ren C; Xu Y; Wu S; Meng C; Pataer A; Song X; Zhang J; Yao Y; He H; Chen H; Ma W; Wang J; Meric-Bernstam F; Champlin RE; Heymach JV; Rooney CM; Swisher SG; Vaporciyan AA; Roth JA; You MJ; Wang M; Fang B
Blood Adv; 2022 Feb; 6(3):891-901. PubMed ID: 34861697
[TBL] [Abstract] [Full Text] [Related]
16. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
Dlouhy I; Karube K; Enjuanes A; Salaverria I; Nadeu F; Ramis-Zaldivar JE; Valero JG; Rivas-Delgado A; Magnano L; Martin-García D; Pérez-Galán P; Clot G; Rovira J; Jares P; Balagué O; Giné E; Mozas P; Briones J; Sancho JM; Salar A; Mercadal S; Alcoceba M; Valera A; Campo E; López-Guillermo A
Br J Haematol; 2022 Feb; 196(3):589-598. PubMed ID: 34632572
[TBL] [Abstract] [Full Text] [Related]
17. PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression.
Yuan S; Wang X; Hou S; Guo T; Lan Y; Yang S; Zhao F; Gao J; Wang Y; Chu Y; Shi J; Cheng T; Yuan W
Leukemia; 2022 Feb; 36(2):370-382. PubMed ID: 34465864
[TBL] [Abstract] [Full Text] [Related]
18. Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and mdm2, in Patients with Solid Tumors and lymphomas Bearing Wild-type TP53.
Saleh MN; Patel MR; Bauer TM; Goel S; Falchook GS; Shapiro GI; Chung KY; Infante JR; Conry RM; Rabinowits G; Hong DS; Wang JS; Steidl U; Naik G; Guerlavais V; Vukovic V; Annis DA; Aivado M; Meric-Bernstam F
Clin Cancer Res; 2021 Oct; 27(19):5236-5247. PubMed ID: 34301750
[TBL] [Abstract] [Full Text] [Related]
19. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):641-649. PubMed ID: 34272171
[TBL] [Abstract] [Full Text] [Related]
20. High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells.
Vernooij L; Bate-Eya LT; Alles LK; Lee JY; Koopmans B; Jonus HC; Schubert NA; Schild L; Lelieveld D; Egan DA; Kerstjens M; Stam RW; Koster J; Goldsmith KC; Molenaar JJ; Dolman MEM
Mol Cancer Ther; 2021 Jun; 20(6):1161-1172. PubMed ID: 33850004
[TBL] [Abstract] [Full Text] [Related]
[Next]
